Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Stereotactic Boost for Poor-Prognosis Oropharyngeal Squamous Cell Carcinoma

NCT01586182 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.

NCT NCT01586182
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01586182 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Stereotactic Boost for Poor-Prognosis Oropharyngeal Squamous Cell Carcinoma
Lead sponsor
Dana-Farber Cancer Institute
Phase
Phase 1/2
Overall status
Withdrawn
Start date
November 30, 2011
Completion date
September 30, 2015
Enrollment
0 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

squamous cell carcinoma of the oropharynx